Search

everythinglearnresearchcommunity

for

Search:↓

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Adolescents with severe alopecia incur significantly higher healthcare costs.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

The document concludes that facial feminization surgery improves psychological well-being and social acceptance for transgender individuals.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Combination therapies for androgenetic alopecia work best but can have significant side effects and costs.

Getting ethical approval for research with children is important but can be complex and time-consuming, sometimes leading to the exclusion of certain age groups.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Wearing a high-quality wig improved a woman's mood and life quality, and the authors suggest insurance should cover the cost of wigs.

Hormone therapy increases facial and body hair in transgender men, while hair removal improves well-being in transgender women, but cost is a barrier as insurance often doesn't cover it. Dermatologists can use various treatments for these hair issues.

Japan improved its regulation of regenerative medicine to ensure safety and prevent unproven treatments.

Direct-to-consumer teledermatology is not effectively reaching underserved populations due to language, technology, and insurance barriers.

People with alopecia areata have similar overall death rates as others but higher risks of death from self-harm, psychiatric issues, and lung cancer in certain cases.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.

No strong proof that platelet-rich plasma effectively treats hair loss.

Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.

Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

Scalp cooling is an effective and safe way to prevent hair loss from chemotherapy, with manageable side effects and low risk of scalp cancer.

Vitiligo is underreported in medical claims and is linked to certain skin types and autoimmune diseases.

Americans see hair transplants as valuable for treating hair loss and want them to be more affordable and tailored to each gender.

Some medications can help increase sexual desire and function in women.